RxDoctor Payments Data

Amardeep Mann, MD

Cardiovascular Disease · Pasco, WANPI 1396715181

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 65.5% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $5,763 and has fallen 63.7% since, to $2,090 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,610in general payments, 2019–2025

Across 211 payments — averaging $97.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14K
  • Abbott$5K
  • Medtronic$841
  • Pfizer$269
  • Takeda Pharmaceuticals U.S.A., Inc.$218
  • Amgen$156
  • plus $929 from 23 others

What the payments were for

  • Speaking & faculty fees$10,50051%
  • Travel & lodging$6,02729%
  • Food & beverage$3,93319%
  • Education$1501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,610 in reported general payments places this provider in the 90th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$82,064
Medicare patients
692
Services billed
1,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$286,303
XareltoRivaroxaban45$53,806
EntrestoSacubitril/Valsartan43$46,072
Metoprolol Succinate254$3,613
Flecainide Acetate68$3,051
Diltiazem 24hr Er (Cd)Diltiazem Hcl41$1,883
Losartan Potassium132$1,005
Isosorbide Dinitrate15$945
Ezetimibe16$700
Digoxin18$698
Carvedilol82$642
Atorvastatin Calcium75$580
Lisinopril65$531
Amlodipine Besylate86$525
Rosuvastatin Calcium43$454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$269$286,303247 claims
Johnson & JohnsonXarelto$36$53,80645 claims
NovartisEntresto$48$46,07243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Pasco

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →